Cardinal Health Inc.: 10-K Risk Factor Changes

2024 vs 2023  ·  SEC EDGAR  ·  2026-06-01
Other years: 2025 vs 2024
✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

35
New Risks
21
Removed
108
Modified
28
Unchanged
🟢 New in Current Filing Supply chain and quality issues could adversely affect operations, profitability, cash flows, and our financial condition. 🔒
🟢 New in Current Filing Changes to the U.S. healthcare environment may not be favorable to us. 🔒
🟢 New in Current Filing We might infringe intellectual property rights or our own intellectual property protections might be insufficient to protect our commercial interests. 🔒
🟢 New in Current Filing Our business and operations depend on the proper functioning of information systems, critical facilities and distribution networks and could be negatively impacted by events outside of our control. 🔒
🟢 New in Current Filing Our sales and credit concentration is significant. 🔒
🟢 New in Current Filing Our business could be affected by events outside of our control including global climate change-related physical and transitional risks, public health crises, natural disasters, geopolitical and other catastrophic events. 🔒
🟢 New in Current Filing Risk Factors 🔒
🟢 New in Current Filing Cybersecurity 🔒
🟢 New in Current Filing Cybersecurity Risk Management 🔒
🟢 New in Current Filing PeriodTotal Numberof SharesPurchased (1)Average Price Paid per ShareTotal Number of SharesPurchasedas Part of Publicly Announced Programs (2)ApproximateDollar Value ofShares That MayYet be PurchasedUnder the Programs (2)(in millions)April 2024157 $107.32 — $3,493 May 2024128 96.95 — 3,493 June 2024134 101.63 — 3,493 Total419 $102.33 — $3,493 🔒
🟢 New in Current Filing Valuation of Goodwill 🔒
🟢 New in Current Filing Revision of Prior Period Consolidated Financial Statements 🔒
🟢 New in Current Filing Notes to Financial Statements 🔒
🟢 New in Current Filing As Reported 🔒
🟢 New in Current Filing Updated Segment Reporting Structure 🔒
🟢 New in Current Filing Notes to Financial Statements 🔒
🟢 New in Current Filing Property and Equipment 🔒
🟢 New in Current Filing Business Combinations 🔒
🟢 New in Current Filing Self-Insurance 🔒
🟢 New in Current Filing Expected Volatility (3) 🔒
🟢 New in Current Filing Notes to Financial Statements 🔒
🟢 New in Current Filing 2. Acquisitions 🔒
🟢 New in Current Filing Fair Value of Assets Acquired and Liabilities Assumed 🔒
🟢 New in Current Filing Identifiable intangible assets: 🔒
🟢 New in Current Filing Identifiable net assets/(liabilities): 🔒
🟢 New in Current Filing Total net assets acquired 🔒
🟢 New in Current Filing Notes to Financial Statements 🔒
🟢 New in Current Filing Department of Justice Civil Investigative Demand 🔒
🟢 New in Current Filing Deferred Income Taxes 🔒
🟢 New in Current Filing 10. Fair Value Measurements 🔒
🟢 New in Current Filing Assets Measured on a Nonrecurring Basis 🔒
🟢 New in Current Filing Net Investment Hedges 🔒
🟢 New in Current Filing 14. Segment Information 🔒
🟢 New in Current Filing Segment Profit 🔒
🟢 New in Current Filing 16. Revision of Previously Issued Financial Statements (Unaudited) 🔒
🔴 No Match in Current Filing Legal proceedings could adversely impact our cash flows or results of operations. 🔒
🔴 No Match in Current Filing Risk Factors 🔒
🔴 No Match in Current Filing PeriodTotal Numberof SharesPurchased (1)Average Price Paid per ShareTotal Number of SharesPurchasedas Part of Publicly Announced Programs (2)ApproximateDollar Value ofShares That MayYet be PurchasedUnder the Programs (3)(in millions)April 2023234 $79.43 — $1,243 May 2023137 83.79 — 1,243 June 20234,588,337 87.18 4,588,208 4,343 Total4,588,708 $87.18 4,588,208 $4,343 🔒
🔴 No Match in Current Filing Major Customers 🔒
🔴 No Match in Current Filing Loss Contingencies 🔒
🔴 No Match in Current Filing Opioid Lawsuits and Investigations 🔒
🔴 No Match in Current Filing Shareholder Securities Litigation 🔒
🔴 No Match in Current Filing Shareholder Derivative Litigation 🔒
🔴 No Match in Current Filing Tax Effects of Goodwill Impairment Charges 🔒
🔴 No Match in Current Filing Tax Effects of Self-Insurance Pre-Tax Loss 🔒
🔴 No Match in Current Filing Tax Effects of Opioid Litigation Charges 🔒
🔴 No Match in Current Filing Balance at end of fiscal year 🔒
🔴 No Match in Current Filing Cash Flow Hedges 🔒
🔴 No Match in Current Filing Notes to Financial Statements 🔒
🔴 No Match in Current Filing Notes to Financial Statements 🔒
🔴 No Match in Current Filing Notes to Financial Statements 🔒
🔴 No Match in Current Filing Schedule II - Valuation and Qualifying Accounts 🔒
🔴 No Match in Current Filing Information About Our Executive Officers 🔒
🔴 No Match in Current Filing Directors and Corporate Governance 🔒
🔴 No Match in Current Filing Directors, Executive Officers, and Corporate Governance 🔒
🔴 No Match in Current Filing Exhibits, Financial Statement Schedules 🔒
🟡 Modified We could continue to suffer the adverse effects of competitive pressures. 🔒
🟡 Modified Sales Returns and Allowances 🔒
🟡 Modified Critical Audit Matters 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified Our results of operations or strategic objectives could be adversely impacted if we fail to manage and complete divestitures. 🔒
🟡 Modified Risk Factors 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified Total share-based compensation expense 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified Legal Proceedings 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified Accumulated Other Comprehensive Loss 🔒
🟡 Modified Risk Factors 🔒
🟡 Modified We could be subject to adverse changes in the tax laws or challenges to our tax positions. 🔒
🟡 Modified 15. Share-Based Compensation 🔒
🟡 Modified Other Civil Litigation 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified Failure to effectively or efficiently complete or manage critical business processes could have unforeseen consequences. 🔒
🟡 Modified Net earnings/(loss) attributable to Cardinal Health, Inc. 🔒
🟡 Modified Cordis IVC Filter Matters 🔒
🟡 Modified Interest Rate, Currency and Commodity Risk 🔒
🟡 Modified Major Customers 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified Restricted Share Units 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified Our business and results of operations could be adversely affected if we experience a material cyber-attack or other systems breach. 🔒
🟡 Modified Five Year Performance Graph 🔒
🟡 Modified Properties and Legal Proceedings 🔒
🟡 Modified Revenue Recognition 🔒
🟡 Modified Changes or uncertainty in U.S. or international trade policies and exposure to economic, political and currency and other risks could disrupt our global operations or negatively impact our financial results. 🔒
🟡 Modified 13. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc. 🔒
🟡 Modified Risk Factors 🔒
🟡 Modified Net deferred income tax liability 🔒
🟡 Modified Income Taxes 🔒
🟡 Modified Goodwill and Other Intangible Assets 🔒
🟡 Modified Financial Statements and Supplementary Data 🔒
🟡 Modified Long-Term Debt 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified Consolidated Statements of Comprehensive Income/(Loss) 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified Employee Retirement Savings Plans 🔒
🟡 Modified Opioid-related legal proceedings and the National Opioid Settlement Agreement we have entered into could have additional or unexpected negative effects on our results of operations or business. 🔒
🟡 Modified Fair Value of Financial Instruments 🔒
🟡 Modified Economic (Non-Designated) Hedges 🔒
🟡 Modified Our Pharmaceutical and Specialty Solutions segment’s profit margin could be adversely affected by changes in industry or market dynamics that we are not able to accurately predict. 🔒
🟡 Modified Antitrust Litigation Proceeds 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified Unrecognized Tax Benefits 🔒
🟡 Modified Other Financing Arrangements 🔒
🟡 Modified Consolidated Statements of Shareholders' Equity/(Deficit) 🔒
🟡 Modified Restructuring and Employee Severance 🔒
🟡 Modified Receivables and Allowance for Doubtful Accounts 🔒
🟡 Modified 11. Financial Instruments 🔒
🟡 Modified Opioid Lawsuits and Investigations 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified 7. Long-Term Obligations and Other Short-Term Borrowings 🔒
🟡 Modified Inventories 🔒
🟡 Modified Earnings/(Loss) before Income Taxes and Provision for/(Benefit From) Income Taxes 🔒
🟡 Modified 12. Shareholders' Equity/(Deficit) 🔒
🟡 Modified Performance Share Units 🔒
🟡 Modified Other Tax Matters 🔒
🟡 Modified Other Intangible Assets 🔒
🟡 Modified Commodity Price Risk Management 🔒
🟡 Modified Cash Flow Hedges 🔒
🟡 Modified 4. Restructuring and Employee Severance 🔒
🟡 Modified Risk Factors 🔒
🟡 Modified Consolidated Statements of Cash Flows 🔒
🟡 Modified products and raw materials available to us and are subject to fluctuations in costs, availability and regulatory risk associated with these products and raw materials. 🔒
🟡 Modified Our goodwill or other long-lived assets may be further impaired, which could require us to record additional significant charges to earnings in accordance with generally accepted accounting principles. 🔒
🟡 Modified Fair Value Hedges 🔒
🟡 Modified Our ability to manage and complete acquisitions could impact our strategic objectives and financial condition. 🔒
🟡 Modified 1. Basis of Presentation and Summary of Significant Accounting Policies 🔒
🟡 Modified Consolidated Balance Sheets 🔒
🟡 Modified Tax Effects of Goodwill Impairment Charges 🔒
🟡 Modified Our business could be affected by activist shareholders. 🔒
🟡 Modified Investments 🔒
🟡 Modified New York Opioid Stewardship Act 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified Risk Factors 🔒
🟡 Modified Currency Exchange Risk Management 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified Vendor Reserves 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified Legal proceedings could adversely impact our cash flows or results of operations. 🔒
🟡 Modified Recently Issued Financial Accounting Standards and Disclosure Rules Not Yet Adopted 🔒
🟡 Modified Amortization and Other Acquisition-Related Costs 🔒
🟡 Modified Effective Tax Rate 🔒
🟡 Modified Assets Held for Sale 🔒
🟡 Modified Risk Factors 🔒
🟡 Modified Balance at end of fiscal year 🔒
🟡 Modified Risk Factors 🔒
🟡 Modified Loss Contingencies 🔒
🟡 Modified Consolidation in the U.S. healthcare industry may negatively impact our results of operations. 🔒
🟡 Modified Risk Factors 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified Our business is subject to rigorous regulatory and licensing requirements. 🔒
🟡 Modified Consolidated Statements of Earnings/(Loss) 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified Notes to Financial Statements 🔒
🟡 Modified Share-Based Compensation 🔒
🟡 Modified 5. Goodwill and Other Intangible Assets 🔒
🟡 Modified Legal Proceedings 🔒
🟡 Modified 3. Divestitures 🔒
164 changes in this historical filing

Historical year-over-year comparisons (2024 vs 2023 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →